An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis

References

• Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book. 2013;33:e236-e240.
   Google Scholar
• Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–1461.
   PubMed Web of Science ®Google Scholar
• Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113:2704–2713.
   PubMed Web of Science ®Google Scholar
• Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116:210–215.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5:3–11.
   PubMedGoogle Scholar
• Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Supportive Oncol. 2007;5:13–21.
   PubMedGoogle Scholar
• Villa A, Sonis ST. Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin Pharmacother. 2016;17:1801–1807.
   PubMed Web of Science ®Google Scholar
• Mortensen HR, Overgaard J, Specht L, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:69–75.
   PubMed Web of Science ®Google Scholar
• Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831.
   PubMed Web of Science ®Google Scholar
• Rose-Ped AM, Bellm LA, Epstein JB, et al. Complications of radiation therapy for head and neck cancers. The patient’s perspective. Cancer Nurs. 2002;25:461–7;quiz 8–9.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–2205.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy–European blood and marrow transplantation mucositis advisory group. J Clin Oncol. 2008;26:1519–1525.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52:61–77. viii.
   PubMedGoogle Scholar
• Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531–1539.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329–336.
   PubMed Web of Science ®Google Scholar
• Russo G, Haddad R, Posner M, et al. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13:886–898.
   PubMed Web of Science ®Google Scholar
• Carlotto A, Hogsett VL, Maiorini EM, et al. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013;31:753–766.
   PubMed Web of Science ®Google Scholar
• Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91–100.
   PubMed Web of Science ®Google Scholar
• Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21:2075–2083.
   PubMed Web of Science ®Google Scholar
• Russi EG, Raber-Durlacher JE, Sonis ST. Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediators Inflamm. 2014;2014:518261.
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC, Melkonian SC, Wang J, et al. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: an informative gene network analysis. PLoS One. 2017;12:e0180396.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Selim MA, El-Sayed NM. alpha-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study. Life Sci. 2017;171:51–59.
   PubMed Web of Science ®Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016;239:115–125.
   PubMed Web of Science ®Google Scholar
• Anderson CM, Sonis ST, Lee CM, et al. Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(2):427–435.
   Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapoor S, et al. Targeting of inflammation for radiation protection and mitigation. Curr Mol Pharmacol. 2018;11(3):203–210.
   Web of Science ®Google Scholar
• Ribeiro SB, de Araujo AA, Araujo Junior RF, et al. Protective effect of dexamethasone on 5-FU-induced oral mucositis in hamsters. PLoS One. 2017;12:e0186511.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389.
   PubMedGoogle Scholar
• Logan RM, Gibson RJ, Sonis ST, et al. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43:395–401.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33:448–460.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7:1139–1145.
   PubMed Web of Science ®Google Scholar
• Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019;27:4023–4033.
   PubMed Web of Science ®Google Scholar
• Bertolini M, Sobue T, Thompson A, et al. Chemotherapy induces oral mucositis in mice without additional noxious stimuli. Transl Oncol. 2017;10:612–620.
   PubMed Web of Science ®Google Scholar
• Beutheu Youmba S, Belmonte L, Galas L, et al. Methotrexate modulates tight junctions through NF-kappaB, MEK, and JNK pathways. J Pediatr Gastroenterol Nutr. 2012;54:463–470.
   PubMed Web of Science ®Google Scholar
• Hwang D, Popat R, Bragdon C, et al. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:321–329.
   PubMed Web of Science ®Google Scholar
• Al-Azri AR, Gibson RJ, Bowen JM, et al. Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. J Oral Pathol Med. 2015;44:459–467.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284.
   PubMed Web of Science ®Google Scholar
• Vasconcelos RM, Sanfilippo N, Paster BJ, et al. Host-microbiome cross-talk in oral mucositis. J Dent Res. 2016;95:725–733.
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3179–3189.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6(Suppl 1):S1-21;quiz S2-4.
   PubMedGoogle Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010;153:358–367.
   PubMed Web of Science ®Google Scholar
• Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29:2808–2814.
   PubMed Web of Science ®Google Scholar
• Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011;29:2815–2820.
   PubMed Web of Science ®Google Scholar
• Anderson CM, Sonis ST, Lee CM, et al. Phase 1b/2a Trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:427–435.
   PubMed Web of Science ®Google Scholar
• Anderson CM, Lee CM, Saunders DP, et al. Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. J Clin Oncol. 2019;37(34):3256–3265. JCO1901507.
   Google Scholar
• Yu HB, Kielczewska A, Rozek A, et al. Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. J Biol Chem. 2009;284:36007–36011.
   PubMed Web of Science ®Google Scholar
• North JR, Takenaka S, Rozek A, et al. A novel approach for emerging and antibiotic resistant infections: innate defense regulators as an agnostic therapy. J Biotechnol. 2016;226:24–34.
   PubMed Web of Science ®Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnol Rep (Amst). 2017;15:24–26.
   PubMedGoogle Scholar
• Limaye SA, Haddad RI, Cilli F, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119:4268–4276.
   PubMed Web of Science ®Google Scholar
• Lee HR, Yoo N, Kim JH, et al. The therapeutic effect of PLAG against oral mucositis in hamster and mouse model. Front Oncol. 2016;6:209.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Shin JM, Shin SH, et al. 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation. Oncotarget. 2017;8:96636–96648.
   PubMedGoogle Scholar
• Jeong J, Kim YJ, Lee DY, et al. 1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation. Cell Biosci. 2019;9:4.
   PubMed Web of Science ®Google Scholar
• Kim GT, Lee DY, Sohn KY, et al. PLAG enhances macrophage mobility for efferocytosis of active neutrophils via membrane redistribution of P2Y2. Cancer Res. 2019;79(13 Suppl):Abstractnr 4586.
   Web of Science ®Google Scholar
• Oronsky B, Goyal S, Kim MM, et al. A review of clinical radioprotection and chemoprotection for oral mucositis. Transl Oncol. 2018;11:771–778.
   PubMed Web of Science ®Google Scholar
• Lentzen G, Schwarz T. Extremolytes: natural compounds from extremophiles for versatile applications. Appl Microbiol Biotechnol. 2006;72:623–634.
   PubMed Web of Science ®Google Scholar
• Schroter MA, Meyer S, Hahn MB, et al. Ectoine protects DNA from damage by ionizing radiation. Sci Rep. 2017;7:15272.
   PubMed Web of Science ®Google Scholar
• Dao VA, Bilstein A, Overhagen S, et al. Effectiveness, tolerability, and safety of ectoine-containing mouthwash versus those of a calcium phosphate mouthwash for the treatment of chemotherapy-induced oral mucositis: a prospective, active-controlled, non-interventional study. Oncol Therapy. 2018;6:59–72.
   PubMed Web of Science ®Google Scholar
• Noszticzius Z, Wittmann M, Kaly-Kullai K, et al. Chlorine dioxide is a size-selective antimicrobial agent. PLoS One. 2013;8:e79157.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis study group. Cancer. 1999;85(10):2103–2113.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published. November 27, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005;63:985–990.
   PubMed Web of Science ®Google Scholar
• Sonis S, Antin J, Tedaldi M, et al. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis. 2013;19:721–727.
   PubMed Web of Science ®Google Scholar
• Alterovitz G, Tuthill C, Rios I, et al. Personalized medicine for mucositis: bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis. Oral Oncol. 2011;47:951–955.
   PubMed Web of Science ®Google Scholar